Cold urticaria: what to do when standard-dosed antihistamine therapy fails to achieve complete symptom control

Cold urticaria is managed first by avoiding cold triggers and taking a regularly dosed modern 2nd generation H1-antihistamine. When that combination does not bring symptoms fully under control, a defined next-line approach is supported by evidence.

Previous line — failure condition

Cold exposure avoidance combined with a standard-dosed 2nd generation H1-antihistamine taken regularly did not meet its goal: complete symptom control with a continuous UAS7 of 0 and absence of wheals and angioedema, as assessed after 2–4 weeks.

Next-line approach — partial overview

The escalation step works within the same drug class as the previous line but changes how it is used. Evidence supports several specific agents at this step. The complete selection criteria, decision algorithm, and clinical considerations are contained in the full protocol.

Treatment target

Complete symptom control — a continuous UAS7 = 0 and a well-controlled disease state — reassessed for adequacy after 2–4 weeks.

Instant Access to Structured Evidence-Based Regimens

References

We recommend updosing of a 2nd generation H1-antihistamine up to fourfold in patients with chronic urticaria unresponsive to a standard-dosed 2nd generation H1-antihistamine as second-line treatment before other treatments are considered.

Studies support the use of up to fourfold standard-dosed bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, and rupatadine.

The goal of treatment is to treat the disease until it is gone and as efficiently and safely as possible aiming at a continuous UAS7 = 0, complete control and a normalization of quality of life.

DOI: 10.1111/all.15090

View source ↗